The GLORY-1 trial, published in *NEJM*, marks a major milestone in obesity pharmacotherapyled by Chinese researchers and powered by dual receptor innovation
The rate of 1 new approval every 20 to 25 years is inadequate and is in stark contrast with the pace of FDA approvals for diabetes medications, which now outnumber AUD medication approvals 20-fold
References: Jensen JK, Binderup T, Grandjean CE, Bentsen S, Ripa RS, Kjaer A
Heart Health Support : Taking care of your heart is crucial
Prescription Medical Weight Loss Programs (Telehealth) Our online weight loss clinic offers non-surgical, physician-supervised prescription weight loss programs
It is a triple hormone receptor agonist, meaning it targets three receptors at once: GIP, GLP-1, and glucagon